SEC Tracker
Get the app

Dianthus Therapeutics DNTH

Dianthus Therapeutics reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash balance of $1.2 billion as of September 30, 2026
  2. Phase 3 EMERGE trial of claseprubart in gMG expected to report top-line results in 2H'28
  3. Phase 3 CAPTIVATE trial in CIDP projected to require less than 200 participants in Part A
  4. Phase 2 MoMeNtum trial in MMN expected to report top-line results in December 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Dianthus Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release, which is furnished but not filed, and is not incorporated by reference into other filings.
  2. The press release is attached as Exhibit 99.1.
  3. The filing was signed by Adam M. Veness, Esq., as the company's SVP, General Counsel, and Secretary.

3 of 3 claims matched the filing text.

From the filing

Item 2.02 Results of Operations and Financial Condition.

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2026, Dianthus Therapeutics, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.11 and is incorporated herein by reference.

The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.2

Description2

99.12

Press release, dated November 4, 20262

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DIANTHUS THERAPEUTICS, INC.

Date:

November 4, 2026

By:3

/s/ Adam M. Veness, Esq.3

Adam M. Veness, Esq.3

SVP, General Counsel and Secretary3

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Stoke Therapeutics STOK public float $592M, Jun 30, 2025
  2. Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
  3. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Evolus EOLS public float $560M, Jun 30, 2025